Greasy Flaking. Stubborn Plaques.
Redness That Keeps Coming Back
No Matter What You Try.
Seborrheic dermatitis is chronic — not because there's no solution, but because most treatments only address one layer of a three-layer problem. This plant-based home system targets Malassezia overgrowth, barrier dysfunction, and internal inflammation simultaneously.
Get the Home Treatment — $260.91 →You've Tried the Medicated Shampoos.
It Comes Back Every Time You Stop.
Seborrheic dermatitis doesn't go away because ketoconazole or selenium sulfide temporarily suppress the Malassezia yeast — and then the condition rebounds when you stop. This is by design of the condition, not a failure of the product. SD is chronic and relapsing. The 2026 expert consensus now formally recommends a maintenance strategy — not just episodic flare treatment — because stopping treatment is the primary driver of relapse.1
The reason is that seborrheic dermatitis isn't purely a fungal problem — it's a convergence of three factors working simultaneously: Malassezia overgrowth, skin barrier dysfunction, and dysregulated immune response. Treating only one of them is why the others keep driving relapse.
Maintenance dosing is now a formal clinical recommendation, not an afterthought. The 2026 international dermatology consensus explicitly states: the goal is a proactive maintenance strategy that prevents relapse — not just treating active flares until clearance, then stopping. This is why the Kapyderm system includes both an active protocol and a distinct weekly maintenance wash step.1
Why Seborrheic Dermatitis
Keeps Coming Back
The most current understanding of seborrheic dermatitis, published in a major 2025 review in Biomedicines, reframes the condition away from "just a Malassezia problem" toward a more complete model: Malassezia overgrowth is the trigger, but immune dysregulation and skin barrier dysfunction are what allow it to cause disease — and both must be addressed for lasting improvement.
"Emerging evidence indicates that immune dysregulation and skin barrier function are likely central to SD pathogenesis, with Malassezia playing a secondary associated role... Malassezia overgrowth may be significant only in individuals predisposed by variations in sebaceous gland function, immune response, and lipid composition."⁴
This reframing is exactly why shampoo-only approaches have a ceiling: they suppress Malassezia temporarily but don't address the dysregulated immune response or the barrier dysfunction that allowed the overgrowth to cause symptoms in the first place. A complete approach targets all three layers — and adds an internal component to address the systemic inflammatory environment that no topical can reach.
Each Component in This System
Addresses a Different Driver
The Kapyderm Seborrheic Dermatitis system was built around the complete clinical picture — not just the fungal surface presentation that medicated shampoos target.
Standard Approaches vs.
A Complete Three-Layer System
| Approach | What it targets | What it misses |
|---|---|---|
| Head & Shoulders (zinc pyrithione) | Antifungal — suppresses Malassezia surface growth | Barrier dysfunction; internal inflammation; plaque dissolution; returns on discontinuation |
| Nizoral (ketoconazole 1%) | Strongest OTC antifungal — directly inhibits Malassezia | Barrier repair; internal inflammation; chronic relapse without maintenance rotation; side effect potential with long-term use |
| Selsun Blue (selenium sulfide) | Antifungal + sebum reduction | Scalp discoloration risk; dries scalp; no barrier repair; no internal component |
| Topical corticosteroids | Anti-inflammatory — fast symptom relief | Skin thinning with long-term use; rebound flare on discontinuation; no antifungal component |
| Roflumilast foam 0.3% (Zoryve) — Prescription | PDE-4 inhibitor — non-steroidal anti-inflammatory; 2026 consensus highlights it as a steroid alternative for face | Prescription only; newer, less long-term safety data; no antifungal component; no internal support⁵ |
| Kapyderm Seborrheic Dermatitis Treatment | All three layers: plaque dissolution + antifungal + barrier repair + internal inflammation | Built as a complete system — no single-mechanism ceiling |
Seborrheic Dermatitis
Presents Differently Across Locations
The same underlying mechanism drives all presentations. The protocol addresses all locations — though the skin-type tonic selection (K1 vs. K2) and plaque pre-treatment step vary by presentation and severity.
The Seborrheic Dermatitis Home Treatment
A 7-component system targeting all three drivers simultaneously: Malassezia control, skin barrier repair, and internal inflammation support. Formulated exclusively with plant-based botanical extracts. EU-regulated — meeting cosmetic safety standards stricter than U.S. FDA requirements.
Active Treatment & Maintenance Protocol
The K1 vs. K2 tonic selection is based on your skin type — dry or oily. Your specialist will confirm during consultation. KS115 is only used when active plaques are present.
- Step 1 (if plaques present): Apply KS115 to affected areas first — allow to absorb
- Step 2: Apply Fungi-Activ to affected areas
- Step 3: Apply K1 (dry skin) or K2 (oily skin) Tonic
- Step 4: Apply Special K Cream to affected areas
- Step 5: Wash with Dandruff Base Cleanser + Ampoule N
- Internal: Take 2 Revital capsules — preferably in the morning
- Apply while dry: Mix Dandruff Base Cleanser + 2ml KS115
- Let sit 5 minutes then emulsify with water and rinse — once per week
- Continue Revital supplement in ongoing cycles
Frequently Asked Questions
Stop Managing the Surface.
Treat All Three Layers.
The Seborrheic Dermatitis Home Treatment addresses Malassezia overgrowth, skin barrier dysfunction, and internal inflammation simultaneously — the complete clinical picture, in one plant-based system.
100% plant-based · EU-regulated · 7-component complete system
- SebDermatology Editorial. Seborrheic Dermatitis Management: What the 2026 Expert Consensus Recommends. Published June 2026. sebdermatology.com. Also: Turchin I, et al. Current Understanding of Seborrheic Dermatitis: Treatment Options. J Cutan Med Surg. 2025 Nov-Dec;29(4_suppl):24S-36S. PMID 40965088
- Tucker D, Masood S. Seborrheic Dermatitis. StatPearls, 2024. Prevalence data 3–5% adults, 85% immunocompromised. NCBI Bookshelf
- Dall'Oglio F, et al. Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden and Pathophysiology. PubMed 2025 Nov-Dec;29(4_suppl):5S-15S. PMID 40965103
- Seborrheic Dermatitis: From Microbiome and Skin Barrier Involvement to Emerging Approaches in Dermocosmetic Treatment. Cosmetics 2024;11(6):208. doi: 10.3390/cosmetics11060208
- Papadakis MA, et al. Seborrheic Dermatitis. Current Medical Diagnosis & Treatment 2026. McGraw Hill Medical. Roflumilast 0.3% foam clinical context.
- Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis and Emerging Therapies. Biomedicines 2025;13(10):2458. PMC12562114